TY - JOUR
T1 - The Potential of Antivirus Compounds in Gletang (Tridax procumbens Linn.) in Inhibiting 3CLpro Receptor of SARS-CoV-2 Virus by In Silico
AU - Islamiati, Yuna
AU - Suryani, Yani
AU - Adawiyah, Ayuni
AU - Taufiqurrohman, Opik
AU - Kharisma, Viol Dhea
AU - Purnamasari, Devi
AU - Soekamto, Nunuk Hariani
AU - Rahaju, Anny Setijo
AU - Kuswati,
AU - Mandeli, Riso Sari
AU - Aledresi, Kawther Ameen Muhammed Saeed
AU - Yusof, Nur Farhana Mohd
AU - Rebezov, Maksim
AU - Yanina, Shimanovskaya
AU - Natalia, Belyakova
AU - Kulikov, Dmitriy
AU - Mullagulova, Gulnara
AU - Zainul, Rahadian
AU - Albari, Muhammad Thoriq
N1 - Publisher Copyright:
© 2022 Phcogj.Com.
PY - 2022/11
Y1 - 2022/11
N2 - SARS-CoV-2 virus has caused pandemic disease since the end of 2019. Virus transmission occurs through droplet and infects the host's respiratory tract rapidly. Viral propagation occurs through translation process of genome +ssRNA, then it being replicated forming some new body parts of virus and assemblied into virions that ready to infect. During the replication process, the translated viral genome in the form of polyprotein will be cut into smaller components by proteases, which one is 3CLpro. The presence of the 3CLpro receptor is used in drug development through in-silico molecular docking process to minimize failures before laboratory test. The antivirus compounds that used to inhibit the 3CLpro receptor are from gletang plant (Tridax procumbens Linn.). This study aim is to determine the value of binding affinity, the interaction between compounds and receptor, and the effect of drug components. The research was conducted by in-silico through the molecular docking process of 3CLpro receptor and antivirus compounds of gletang (Tridax procumbens Linn.), including betulinic acid, kaempferol and lignan. The results showed that the binding affinity of betulinic acid was -6.6 kcal/mol, kaempferol was -5.6 kcal/ mol and lignan was -5.4 kcal/mol. The interaction form of compounds and receptor was hydrogen bond, electrostatic, hydrophobic, and van der Waals. Compared to baicalein compound as a positive control with the value of binding affinity was -6.7 kcal/mol and its interaction with 3CLpro receptor, showed betulinic acid, kaempferol and lignan have smaller ability but they have the potential to inhibit the 3CLpro receptor.
AB - SARS-CoV-2 virus has caused pandemic disease since the end of 2019. Virus transmission occurs through droplet and infects the host's respiratory tract rapidly. Viral propagation occurs through translation process of genome +ssRNA, then it being replicated forming some new body parts of virus and assemblied into virions that ready to infect. During the replication process, the translated viral genome in the form of polyprotein will be cut into smaller components by proteases, which one is 3CLpro. The presence of the 3CLpro receptor is used in drug development through in-silico molecular docking process to minimize failures before laboratory test. The antivirus compounds that used to inhibit the 3CLpro receptor are from gletang plant (Tridax procumbens Linn.). This study aim is to determine the value of binding affinity, the interaction between compounds and receptor, and the effect of drug components. The research was conducted by in-silico through the molecular docking process of 3CLpro receptor and antivirus compounds of gletang (Tridax procumbens Linn.), including betulinic acid, kaempferol and lignan. The results showed that the binding affinity of betulinic acid was -6.6 kcal/mol, kaempferol was -5.6 kcal/ mol and lignan was -5.4 kcal/mol. The interaction form of compounds and receptor was hydrogen bond, electrostatic, hydrophobic, and van der Waals. Compared to baicalein compound as a positive control with the value of binding affinity was -6.7 kcal/mol and its interaction with 3CLpro receptor, showed betulinic acid, kaempferol and lignan have smaller ability but they have the potential to inhibit the 3CLpro receptor.
KW - 3CLpro receptor
KW - Antivirus
KW - Gletang
KW - In-silico
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85146176868&partnerID=8YFLogxK
U2 - 10.5530/pj.2022.14.170
DO - 10.5530/pj.2022.14.170
M3 - Article
AN - SCOPUS:85146176868
SN - 0975-3575
VL - 14
SP - 796
EP - 805
JO - Pharmacognosy Journal
JF - Pharmacognosy Journal
IS - 6
ER -